Compound Detail
CHEMBL302795
TENOXICAM 🧪 Phase II
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
🧪 Phase II
Basic Information
| ChEMBL ID | CHEMBL302795 |
| Name | TENOXICAM |
| Phase | Phase II |
| Structure Type | MOL |
| InChI Key | LZNWYQJJBLGYLT-UHFFFAOYSA-N |
| Therapeutic | ✓ Yes |
2
Targets
2
Activities
1
Assay Types
10
PK Parameters
20
Publications
8
Known Names
2
Indications
Molecular Properties
337.4
MW (Da)
1.64
ALogP
6
HBA
2
HBD
99.6
PSA (Ų)
0.87
QED
0
Ro5 Violations
2
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| Chirality | Achiral |
Indications
Rheumatic Diseases Pain
ATC Classification
M01AC02
tenoxicam
Level 1: MUSCULO-SKELETAL SYSTEM
Level 2: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
Activity Summary
IC50 2 meas. best 5.94
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Prostaglandin G/H synthase 1 CHEMBL221 | IC50 | 5.94 | 5.94 | 1140.0 | 1 |
| Unchecked CHEMBL612545 | IC50 | 4.3 | 4.3 | 49500.0 | 1 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| CL | 0.073 | mL.min-1.kg-1 | Homo sapiens |
| CL | 0.03 | mL.min-1.kg-1 | Homo sapiens |
| CL | 0.0297 | mL.min-1.kg-1 | Homo sapiens |
| CL | 0.03 | mL.min-1.kg-1 | Homo sapiens |
| CL | 0.03 | mL.min-1.kg-1 | Homo sapiens |
| F | 80.0 | % | Homo sapiens |
| Fu | 0.0085 | - | Homo sapiens |
| Fu | 0.0085 | - | Homo sapiens |
| MRT | 92.0 | hr | Homo sapiens |
| T1/2 | 67.0 | hr | Homo sapiens |
Activity Data Samples
Top measurements by pChEMBL value
| Target | Type | Rel. | Value | Units | pChEMBL | Assay | PubMed |
|---|---|---|---|---|---|---|---|
| Prostaglandin G/H synthase 1 | IC50 | = | 1140.0 | nM | 5.94 | DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid) | - |
| Unchecked | IC50 | = | 49500.0 | nM | 4.3 | Inhibition of soybean 15-LOX | 37862815 |
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| - | 10.5281/zenodo.13943903 | ADMET | 89 |
| 31158845 | 10.1038/s41586-019-1291-3 | ADMET | 55 |
| 15646539 | 10.1016/s0399-8320(04)95062-2 | Unchecked | 11 |
| 15646539 | 10.1016/s0399-8320(04)95062-2 | NON-PROTEIN TARGET | 8 |
| 20070106 | 10.1021/jm901371v | Homo sapiens | 8 |
| 18426954 | 10.1124/dmd.108.020479 | ADMET | 4 |
| 31995375 | 10.1021/acs.jmedchem.0c00046 | Albumin | 4 |
| 20869876 | 10.1016/j.bmc.2010.08.052 | Albumin | 4 |
| 38747896 | 10.1021/acs.jmedchem.4c00596 | No relevant target | 4 |
| 20014752 | 10.1021/tx900326k | Hepatotoxicity | 3 |
| 37468498 | 10.1038/s41467-023-40064-9 | Cannabinoid receptor 1 | 3 |
| 3494124 | 10.1021/jm00387a017 | Rattus norvegicus | 3 |
| - | 10.6019/CHEMBL4808148 | Histone deacetylase 6 | 3 |
| 19445515 | 10.1021/jm900403j | Homo sapiens | 2 |
| 23378628 | 10.1124/dmd.112.050054 | ADMET | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Mu-type opioid receptor | 2 |
| - | 10.6019/CHEMBL4651402 | SARS-CoV-2 | 2 |
| 15267234 | 10.1021/jm040760a | No relevant target | 2 |
| 10891117 | 10.1021/jm0000564 | ADMET | 2 |
| 10891117 | 10.1021/jm0000564 | No relevant target | 2 |
Data from ChEMBL 36 via Core Engine